Roche's Hemlibra Faces Tough Competition: Analysts Provide Mixed Ratings and Forecasts
On Monday, Jefferies maintained its Hold rating on Roche Holding stock with a price target of CHF240.00. The firm's stance comes as Roche prepares to defend its Hemlibra product against upcoming competition from Novo Nordisk's mim8.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
